Navigation Links
Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
Date:3/3/2008

MINNEAPOLIS, March 3 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) announced today the presentation of the findings of three studies on its Urgent(R) PC Neuromodulation System, a proprietary, minimally invasive nerve stimulation device, designed for office-based treatment of overactive bladder (OAB) symptoms, at the Society of Urologic Nurses and Associates (SUNA) Annual Symposium in Tampa, Florida. These retrospective and observational studies examined the use of the Urgent PC to deliver percutaneous tibial nerve stimulation (PTNS) for the treatment of OAB symptoms of urinary urgency, urinary frequency, and urge incontinence.

"These studies found that the Urgent PC is a viable, well-tolerated, nondrug option for the delivery of PTNS for treatment of OAB symptoms. The studies also reported reductions in the frequency of unwanted voids and incontinence, as well as a high level of self-reported patient satisfaction," said Dave Kaysen, the President and Chief Executive Officer of Uroplasty, Inc. "We believe, from a practice perspective, that Urgent PC is an effective, easy-to-administer treatment easily incorporated into routine patient care in an office setting."

In an oral presentation, "Percutaneous Tibial Nerve Stimulation: Revival of an Old Technology for Treatment of Overactive Bladder," Leslie Wooldridge, MSN, RNCS, GNP.F, BCIA-PMBD, Director of the Bladder Control Clinic from Hackley Health at the Lakes Women's Center in Muskegon, Michigan, presented results of 24 patients, who completed the initial twelve, 30-minute weekly Urgent PC treatments. Of the 24 patients, 19 patients with successful results transitioned to maintenance therapy with longer intervals between treatments. Two did not find the Urgent PC effective enough to continue the treatments and three discontinued the treatment for reasons unrelated to the treatment itself. Patients found a reduction in the daily average number of day voids from 11.16 to 8, night voids from 2.46 to 1.09 and incontinence episodes from 3.78 to 0.75.

In a poster presentation, "Percutaneous Tibial Nerve Stimulation (PTNS) Treatment for Overactive Bladder (OAB) Patients in a Community Based Urology Practice," Lesbia Candelaria, RN from Winter Park Urology Associates, Orlando, Florida, conducted a retrospective evaluation of sixteen patients, who successfully completed twelve, 30-minute weekly Urgent PC treatments. Ms. Candelaria collected data on demographics, night voids and subjective patient satisfaction and improvement at the end of the treatment schedule. Of the 16 patients who completed the treatments, 5 were female and 11 were male. The data showed decreases in the average night voids and a high rate of patient satisfaction with the treatment. The response to the survey questions indicated that after 12 treatments:

-- Greater than 50% of the patients improved night voids from a baseline

average of 3.6 to an average of 1.8.

-- Greater than 80% of patients were totally or highly satisfied with the

Urgent PC treatments.

-- Approximately 72% of patients rated themselves as highly or totally

improved.

-- 100% of the patients who answered this question (n=8) said they would

definitely or likely recommend Urgent PC treatments to a friend with

similar symptoms.

In another poster presentation, "Percutaneous Tibial Nerve Stimulator: A Viable Option for Urgency, Frequency, and Urge Incontinence," Vanessa K. Hardy, WHNP, APN, MSN, a urogynecology nurse practitioner from Vanderbilt University Medical Center in Nashville, Tennessee, conducted a retrospective review of 12 Urgent PC patients. Ms. Hardy collected data on primary diagnosis, duration of treatment, and changes in urinary frequency, urgency, and urge incontinence. Following the twelve, 30-minute weekly Urgent PC treatments, 30% of the patients (or 4 patients) reported at least 50% or more improvement in their symptoms.

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of OAB symptoms of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to the symptoms of OAB. Uroplasty sells the Urgent PC system in the United States, Canada and countries recognizing the CE mark. Outside of the United States, the Urgent PC is also indicated for the treatment of fecal incontinence.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA- approved non-surgical neurostimulation therapy for the treatment of overactive bladder (OAB) symptoms. We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer,

952.426.6140

EVC Group

Julie Huang/Matt Selinger (Investors)

646.443.6963

Steve DiMattia/Chris Gale (Media)

646.201.5445


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
2. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
3. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology: